Article
Power and sample size calculations for SNP association studies with censored time-to-event outcomes.
Genetic epidemiology - 1 Sept 2012
Owzar Kouros, Li Zhiguo, Cox Nancy, Jung Sin-Ho
Abstract excerpt
For many clinical studies in cancer, germline DNA is prospectively collected for the purpose of discovering or validating single-nucleotide polymorphisms (SNPs) associated with clinical outcomes. The primary clinical endpoint for many of these studies are time-to-event outcomes such as time of death or disease progression which are subject to censoring mechanisms. The Cox score test can be readily employed to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
